Rigel's bleeding disorder drug clears first of two key trials

(Reuters) – Rigel Pharmaceuticals Inc said its experimental drug to treat a bleeding disorder met its main goal in the first of two late-stage trials, sending its shares up 12 pct in premarket trade.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *